OPEN Foundation

Psychedelic Q&A with Rick Doblin, PhD

🗣 Rick Doblin, President and Founder of the 37-year-old Multidisciplinary Association for Psychedelic Studies (MAPS)

⏰ Wednesday 4 October, 8PM CET (7PM GMT, 2PM EST, 11AM PST)

📍 Online (OPEN Community Platform)

Join Rick Doblin, PhD, President and Founder of the 37-year-old Multidisciplinary Association for Psychedelic Studies (MAPS), for a Q&A session.

Bring your questions about MAPS, psychedelic-assisted therapy, the tension between medicalization and legalization, the path to U.S. FDA approval and globalization for MDMA-assisted therapy for PTSD, challenges in the path toward European approvals, the future of psychedelics, or other psychedelic topics.

 

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

Unlock access to this and all exclusive events with leading psychedelic experts and engage in real time through the OPEN Community Membership. Plus, enjoy a community space, a content library, discounts, and more.

ATTEND WITH A SMALL DONATION

Not ready to become an OPEN community member? You can attend this event through a small one-time donation to help support the OPEN Foundation, a leading nonprofit dedicated to advancing psychedelic research since 2007.

Really want to attend but can’t afford a donation? Apply for a one-time free access here.

ABOUT THE SPEAKER

Rick Doblin is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. 

His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. 

His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys.

WHAT'S UNIQUE ABOUT THIS EVENT?

Attending this online event is an interactive experience, unlike watching a lecture on YouTube or a webinar. You'll have the chance to connect with the speakers directly and ask questions, allowing you to explore the topic in greater depth.

ICPR 2024

DIVERSITY SCHOLARSHIPS

When you choose to attend this event with a one-time donation, 100% of proceeds will be used to provide full scholarship tickets for the members of indigenous communities to attend ICPR 2024! Thank you for supporting diversity initiatives and the OPEN’s nonprofit mission of advancing psychedelic science and therapy.

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

Unlock access to this and all exclusive events with leading psychedelic experts and engage in real time through the OPEN Community Membership. Plus, enjoy a community space, a content library, discounts, and more.

ATTEND WITH A SMALL DONATION

Not ready to become an OPEN community member? You can attend this event through a small one-time donation to help support the OPEN Foundation, a leading nonprofit dedicated to advancing psychedelic research since 2007.

Really want to attend but can’t afford a donation? Apply for a one-time free access here.

ALREADY A MEMBER?

To access the OPEN Community Platform, click the button below. The platform not only live streams all events, but also provides direct access to event recordings.

22 May - Delivering Effective Psychedelic Clinical Trials

X